Neuroscience Today—May 13, 2026

This week’s Neuroscience update highlights regulatory actions, clinical progress, diagnostic advances, partnerships, and access developments across CNS care.

In Today’s Newsletter

Dive deeper

🧠 Johnson & Johnson launches Generation Fine depression campaign [1] [US • 07 May 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission
Context: Generation Fine is a global campaign for people with major depressive disorder, informed by a seven-country survey.
Key point: Johnson & Johnson said nearly 4 in 5 surveyed patients with MDD do not believe antidepressants will help them reach remission.
Implication: May expand screening, initiation, and follow-up at scale.

☢️ Plus Therapeutics presents REYOBIQ data in leptomeningeal metastases [2] [US • 08 May 2026]

https://www.globenewswire.com/news-release/2026/05/08/3291010/0/en/plus-therapeutics-announces-oral-presentation-highlighting-reyobiq-clinical-and-translational-data-demonstrating-favorable-safety-survival-and-emerging-immunomodulation-in-leptomen.html
Context: The AANS plenary reviewed Phase 1 ReSPECT-LM data for REYOBIQ (rhenium Re186 obisbemeda) in leptomeningeal metastases.
Key point: Plus Therapeutics reported favorable safety, survival signals, targeted radiation delivery, and emerging immunomodulation.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 GC Biopharma wins Peru approval for Hunterase ICV [3] [Peru • 07 May 2026]

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=31556
Context: Hunterase ICV is an intracerebroventricular therapy for Hunter syndrome, with prior approvals in Japan and Russia.
Key point: GC Biopharma said Peru’s DIGEMID granted marketing authorization for Hunterase ICV.
Implication: Introduces competition that may affect pricing and formulary access.

👃 Oncotelic closes N2B asset transfer with Lunai Bioworks [4] [US • 06 May 2026]

https://www.globenewswire.com/news-release/2026/05/06/3288811/0/en/oncotelic-therapeutics-announces-closing-of-a-strategic-monetization-of-its-cns-nasal-assets-with-lunai-bioworks-advancing-joint-development-in-biodefense-and-alzheimer-s-disease.html
Context: The transaction covers Oncotelic’s N2B nose-to-brain delivery system within biodefense and Alzheimer’s disease.
Key point: Oncotelic received $12.5 million in Lunai Bioworks Series B Convertible Preferred Stock for field-specific rights.
Implication: Signals pipeline investment and modality expansion.

💉 Ajovy gains Korea pediatric episodic migraine prevention approval [5] [Korea • 06 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31549
Context: Ajovy (fremanezumab; Teva-Handok) targets CGRP and was studied in the Phase 3 SPACE-EM pediatric episodic migraine trial.
Key point: Korea’s MFDS approved Ajovy for prevention of episodic migraine in patients aged 6–17 years weighing at least 45 kg.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 FDA extends LEQEMBI IQLIK starting-dose review [6] [US • 08 May 2026]

https://investors.biogen.com/news-releases/news-release-details/update-fda-priority-review-leqembir-iqliktm-lecanemab-irmb
Context: LEQEMBI IQLIK (lecanemab-irmb; Eisai, Biogen) is under FDA Priority Review as a once-weekly subcutaneous starting dose for early Alzheimer’s disease.
Key point: FDA extended the sBLA review by three months, setting a new PDUFA action date of 24 Aug 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Roche receives CE mark for Elecsys pTau217 Alzheimer’s blood test [7] [EU • 12 May 2026]

https://www.roche.com/media/releases/med-cor-2026-05-12
Context: Elecsys pTau217 (Roche, Eli Lilly collaboration) is a blood test intended to rule in or rule out amyloid pathology.
Key point: Roche received CE mark for Elecsys pTau217 for use across primary and secondary care in people with cognitive symptoms.
Implication: May expand screening, initiation, and follow-up at scale.

🧒 FDA approves Ocrevus for pediatric RRMS ages 10+ [8] [US • 08 May 2026]

https://www.patientcareonline.com/view/fda-approves-ocrelizumab-ocrevus-for-relapsing-remitting-multiple-sclerosis-in-patients-over-10-years-old
Context: Ocrevus (ocrelizumab; Genentech) is an anti-CD20 monoclonal antibody evaluated in Phase 3 OPERETTA II.
Key point: FDA approved IV Ocrevus for pediatric RRMS in patients aged 10+ who weigh at least 25 kg.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it Matters

CNS care is moving toward earlier intervention, with campaigns, diagnostics, and pediatric approvals targeting diagnosis and treatment gaps.
Alzheimer’s updates span both therapeutics delivery and blood-based pathology testing, reinforcing pressure on care pathways.
Pediatric neurology access expanded in Korea migraine prevention and US relapsing-remitting MS.
Rare CNS and oncology programs continue to seek differentiated delivery, radiation, and immunomodulatory approaches.
Regulatory and partnership moves may affect formulary access, trial strategy, and patient identification.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page

🎯 Catch up on the Top Neuroscience news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Johnson & Johnson’s Generation Fine campaign?

Generation Fine is a global Johnson & Johnson campaign encouraging people with major depressive disorder to discuss residual symptoms and remission goals with healthcare providers. It draws on a seven-country survey and Mental Health America expertise. [1]

What did Plus Therapeutics present for REYOBIQ?

Plus Therapeutics presented Phase 1 ReSPECT-LM and translational data for REYOBIQ in leptomeningeal metastases at AANS 2026. The company described favorable safety, survival signals, targeted delivery, and emerging immune effects. [2]

What did Peru approve for GC Biopharma?

Peru’s DIGEMID granted marketing authorization for Hunterase ICV, GC Biopharma’s intracerebroventricular Hunter syndrome therapy. The approval follows prior authorizations in Japan and Russia. [3]

What rights did Oncotelic transfer to Lunai Bioworks?

Oncotelic transferred field-specific worldwide rights to its N2B nose-to-brain delivery system for biodefense medical countermeasures and Alzheimer’s disease. Oncotelic said it received $12.5 million in Lunai Bioworks preferred stock. [4]

What is the new Korea indication for Ajovy?

Korea’s MFDS approved Ajovy (fremanezumab) for prevention of episodic migraine in patients aged 6–17 years who weigh at least 45 kg. Teva-Handok said the approval was based on Phase 3 SPACE-EM data. [5]

What changed in the LEQEMBI IQLIK FDA review?

FDA extended the review of LEQEMBI IQLIK as a subcutaneous starting dose for early Alzheimer’s disease by three months. The new PDUFA action date is 24 Aug 2026. [6]

Entities / Keywords

Johnson & Johnson, J&J, Generation Fine, major depressive disorder, MDD, remission, Mental Health America, Kyle Long
Plus Therapeutics, REYOBIQ, rhenium Re186 obisbemeda, ReSPECT-LM, leptomeningeal metastases, AANS 2026
GC Biopharma, Hunterase ICV, Hunter syndrome, DIGEMID, Peru, intracerebroventricular therapy
Oncotelic Therapeutics, Lunai Bioworks, N2B delivery system, nose-to-brain, biodefense, Alzheimer’s disease
Teva-Handok, Ajovy, fremanezumab, CGRP, pediatric episodic migraine, SPACE-EM, MFDS, Korea
Eisai, Biogen, LEQEMBI IQLIK, lecanemab-irmb, early Alzheimer’s disease, sBLA, PDUFA
Roche, Eli Lilly, Elecsys pTau217, phosphorylated tau 217, amyloid pathology, CE mark, Alzheimer’s diagnostics
Genentech, Ocrevus, ocrelizumab, anti-CD20, pediatric RRMS, OPERETTA II, FDA